NattoPharma has secured patents in Canada and South Korea for its proprietary process of synthesizing MenaQ7 PharmaPure Vitamin K2.
NattoPharma (East Brunswick, NJ), now a part of Gnosis by Lesaffre, has secured patents in Canada and South Korea for its nature-identical synthesis which creates MenaQ7 PharmaPure Vitamin K2 as MK-7. The South Korean certificate of patent #10-2229841, “Process for preparation of MK-7 type of vitamin K2” was issued on March 15, 2021, and the Canadian patent #22,888,010 was issued on May 25, 2021.
“This unique patented process results in the world’s only truly all-trans synthetic Vitamin K2 as MK-7,” said William Sommer, NattoPharma’s vice president of Global Development & Regulatory, in a press release. “Our material is recognized as being of the highest quality, to which it is currently being utilized in multiple studies sponsored by the traditional medical community. This technology also ensures supplement manufacturers deliver the MK-7 with the health benefits customers’ desire.”
He adds that because of the significant intellectual and monetary investments the company has made into the technology, NattoPharma is committed to actively monitoring market developments to protect its intellectual property rights.
“The approval of these patents represents another milestone for NattoPharma and its partners,” stated Sophie Legrain-Raspaud, Global Research and Applications director with Gnosis by Lesaffre. “This further strengthens our combined global IPR‐platform and improves our competitive position within the food supplement market. It is a wonderful development for NattoPharma and conveys the overwhelming promise of our recent merger.”